Traci McCarty | BioMarin Pharmaceutical, Inc. |
Jean-Jacques Bienaimé | BioMarin Pharmaceutical, Inc. |
Jeffrey Robert Ajer | BioMarin Pharmaceutical, Inc. |
Daniel K. Spiegelman | BioMarin Pharmaceutical, Inc. |
Henry J. Fuchs, M.D. | BioMarin Pharmaceutical, Inc. |
Joseph P. Schwartz | Leerink Partners LLC |
Salveen Richter | Goldman Sachs & Co. LLC |
Christopher J. Raymond | Piper Jaffray & Co. |
Carmen Augustine | JPMorgan Securities LLC |
Srikripa Devarakonda | Citigroup Global Markets, Inc. |
Martin Auster | Credit Suisse Securities (NYSE:USA) LLC |
Aspen Mori | Merrill Lynch, Pierce, Fenner & Smith, Inc. |
Eliana Merle | Cantor Fitzgerald |
Paul Matteis | Stifel Financial Corp. |
Kennen Mackay | RBC Capital Markets LLC |
Gena Wang | Barclays Capital, Inc. |
Vincent Chen | Sanford C. Bernstein & Co. LLC |
Myles Minter | William Blair |
Joseph Thome | Cowen & Co. LLC |
Welcome to the BioMarin Third Quarter 2018 Financial Results Conference Call. Hosting the conference call today from BioMarin is Traci McCarty, Vice President of Investor Relations. Please go ahead, Traci.
Thank you. To remind you, today's call is non-confidential and contains forward-looking statements about the business prospects of BioMarin Pharmaceutical, including expectations regarding BioMarin's financial performance, commercial products and potential future products in different areas of therapeutic research and development.